Neurocrine Biosciences (NBIX) Tops Q3 EPS by 29c, Beats on Revenue; Offers FY24 Revenue Guidance

Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $1.81, $0.29 better than the analyst estimate of $1.52. Revenue for the quarter came in at $622.1 million versus the consensus estimate of $600.97 million.

GUIDANCE:

Neurocrine Biosciences sees FY2024 revenue of $2.3-2.32 billion, versus the consensus of $2.33 billion.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.

You May Also Be Interested In

• RBC Capital on Neurocrine Bio. (NBIX): 'We like the setup and remain buyers'
• HSBC Raises S&P500 Target to 8,100
• Al Shams plans to nominate majority board slate at Braemar Hotels